Catalyst Dossier · compiled by CeliA 🧫

KAZIA THERAPEUTICS LTD (KZIA)

Pharmaceutical Preparations · market cap $11.2B · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-10-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Kazia Therapeutics (KZIA) is a small-cap pharmaceutical company with 6 employees and a market cap of approximately $11.2 billion, trading near $12.98. Its lead asset is Paxalisib (GDC-0084), a Phase 2 candidate being evaluated in adult glioblastoma. No near-term catalysts are listed on the calendar and no recent catalysts have been disclosed.

The catalyst path

2026-10-15 (est.)Phase 2 · Abemaciclibimp 7/10
2026-12-01 (est.)Phase 2 · PAXALISIBimp 7/10

Pipeline

Asset	Phase	Indication
Paxalisib (GDC-0084)	Phase 2	Glioblastoma, Adult
Abemaciclib	Phase 2	CDK Gene Mutation
Opdualag	Phase 2	Childhood Cancer
PAXALISIB	Phase 2	Primary Central Nervous System Lymphoma
Temozolomide capsule	Phase 2	Malignant Primary Gliomas
Lomustine	Phase 3	Glioblastoma

Price & technical context

3-month

-2.2%

6-month

+163.0%

12-month

+62.4%

52-wk range

$5.00–$15.72

vs 50-day MA

+2.7%

vs 200-day MA

+34.4%

Realized vol

118.1%

Max drawdown

-90.9%

Daily closes through 2026-08-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for KZIA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.